Cell therapy is a therapy where functional healthy cells are injected into a patient to perform a therapeutic intervention. MedXCell Science develops such therapies using mesenchymal stromal cells (MSCs), naturally present in human bodies and particularly in adipose tissue. MSCs have shown benefits including anti-inflammatory and immunomodularity properties that can be used for therapeutic purpose.
Such treatment can be considered an essential new tool for the treatment of osteoarthritis, offering long term symptomatic relief, encouraging tissue repair, delaying need for surgical interventions, and reducing drug side effects and dependency. It will rapidly become the treatment of choice – an effective, safe and cost-effective long-term solution for sufferers of this debilitating condition.
MedXCell Science’s cell therapy products are subject to extensive research and product development. Clinical trials are conducted to full quality and regulatory standards enabling MedXCell Science to file an application for marketing authorization at its successful conclusion.
MedXCell Science has already made the transition into a clinical stage company through its involvement in pan-European clinical studies. Leveraging on the research of prominent experts in the cell therapy area and the results achieved at the Institute the Institute of Regenerative Medicine and Biotherapy (IRMB) located in the CHU of Montpellier (France), MedXCell Science is now in the process of starting the final phase of clinical trial before commercialization for its first product candidate, ADIPOA.
MedXCell Science’s lead product candidate, ADIPOA©, is an off-the-shelf allogeneic therapeutic dose in an injectable form that intends to treat mild to moderate knee osteoarthritis. ADIPOA will be a safe, cost-effective and non-invasive treatment for long-term relief.